Carotid body tumor screening

Jump to: navigation, search

Carotid body tumor Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Carotid Body Tumor from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Carotid body tumor screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Carotid body tumor screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Carotid body tumor screening

CDC on Carotid body tumor screening

Carotid body tumor screening in the news

Blogs on Carotid body tumor screening

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Carotid body tumor screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2] Maria Fernanda Villarreal, M.D. [3]

Overview

There is insufficient evidence to recommend routine screening for the carotid body tumor. However, patients who manifested the symptoms before the age of 50 years old, those with a positive family history and those with multiple paragangliomas has been recommended to undergo additional testing.

Screening

 
 
 
 
 
 
 
 
 
 
 
Patient with carotid body tumor
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
History, Physical examination, and evaluation of cnotralateral side
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients with age < 50 years
Patients with multiple paraganglioma
Patients with a positive family history
 
 
 
The rest of the patients
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SDHD genetic testing
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presence of SDHD mutation
 
 
 
 
Absence of SDHD mutation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SDHC and SDHB genetic testing
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presence of SDHC/SDHB mutation
 
 
 
Absence of SDHC/SDHB mutation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All the relatives should be evaluated for the presence of paragnaglioma
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
whole-body F-dihydroxyphenylalanine (F-DOPA) positron emission tomography to assess the presence of other paragangliomas
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presence of other paraganglioma
 
 
 
Absence of other paraganglioma
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24-hour urine catecholamines and MRI for biochemical screening
 
 
 
surveillance screening every 5 years

References

  1. Davila, Victor J.; Chang, James M.; Stone, William M.; Fowl, Richard J.; Bower, Thomas C.; Hinni, Michael L.; Money, Samuel R. (2016). "Current surgical management of carotid body tumors". Journal of Vascular Surgery. 64 (6): 1703–1710. doi:10.1016/j.jvs.2016.05.076. ISSN 0741-5214.